RXi Pharmaceuticals (RXII) Receives Daily Coverage Optimism Rating of 0.29

Media stories about RXi Pharmaceuticals (NASDAQ:RXII) have been trending positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. RXi Pharmaceuticals earned a daily sentiment score of 0.29 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.7713683829575 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of RXi Pharmaceuticals (RXII) opened at $0.63 on Monday. RXi Pharmaceuticals has a 1 year low of $0.32 and a 1 year high of $1.88.

RXi Pharmaceuticals (NASDAQ:RXII) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). During the same quarter in the prior year, the firm posted ($0.34) earnings per share. research analysts predict that RXi Pharmaceuticals will post -0.74 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “RXi Pharmaceuticals (RXII) Receives Daily Coverage Optimism Rating of 0.29” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/12/11/rxi-pharmaceuticals-rxii-receives-daily-coverage-optimism-rating-of-0-29.html.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Insider Buying and Selling by Quarter for RXi Pharmaceuticals (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply